Jatenzo

How Hard Is It to Find Jatenzo in Stock?

Jatenzo is not on the FDA's official drug shortage list. The medication is available from Tolmar, Inc. and distributed nationally. However, because it is a brand-name-only specialty medication with a high retail price, most standard retail pharmacies do not keep Jatenzo in stock routinely. Patients typically need to call pharmacies to find one that either stocks it or is willing to special-order it within 1–3 business days.

Insurance barriers — including prior authorization requirements, step therapy policies, and Tier 3 or non-formulary placement — are the most significant access obstacles for many patients. Medicare Part D patients face particular challenges as the drug is generally not covered without a formulary exception. The broader injectable testosterone shortage (ongoing since early 2023) has also increased demand for oral TRT options, including Jatenzo.

If you're having trouble finding Jatenzo at your pharmacy, medfinder calls pharmacies near you to find which ones can fill your prescription — saving you hours of phone calls. Tolmar's contracted pharmacy network also offers significantly reduced pricing ($185/month for cash patients) for those who fill through participating pharmacies.

Who Can Prescribe Jatenzo?

Jatenzo is a Schedule III controlled substance (CIII) under the DEA. It must be prescribed by a licensed healthcare provider with DEA registration to prescribe controlled substances. The prescribing information requires confirmation of diagnosis through at least two morning serum testosterone measurements below the normal range on separate days before initiating therapy.

Healthcare providers who commonly prescribe Jatenzo include:

Urologists — frequently the first specialist for male hypogonadism

Endocrinologists — specialists in hormonal disorders; experienced with complex hypogonadism cases

Primary care physicians (internists, family medicine) — may prescribe for straightforward cases

Nurse practitioners (NPs) and physician assistants (PAs) — can prescribe controlled substances in most states; commonly prescribe TRT at men's health and urology practices

Jatenzo is also available through telehealth platforms in states that allow controlled substance prescribing via telemedicine without a prior in-person visit. However, many telehealth TRT providers focus primarily on injectable testosterone formulations. Patients specifically seeking Jatenzo may find greater success with an in-person urology or endocrinology practice or a men's health clinic experienced with all TRT formulations.

Is Jatenzo a Controlled Substance?

Yes. Jatenzo is classified as a Schedule III controlled substance (CIII) under the DEA Controlled Substances Act. This is because it contains testosterone, an anabolic androgen that can be a target for misuse and abuse at doses higher than those prescribed for medical use.

As a Schedule III controlled substance, Jatenzo requires a valid prescription from a licensed prescriber with DEA authority to prescribe controlled substances. In most states, refills require a new prescription (up to 5 refills may be authorized within 6 months, depending on state law). Patients must store Jatenzo securely and never share it with others — selling or giving away a Schedule III controlled substance is illegal.

DEA scheduling does not affect the clinical appropriateness of Jatenzo for properly diagnosed patients. Prescribers qualified to treat hypogonadism — including urologists, endocrinologists, PCPs, NPs, and PAs — can prescribe Jatenzo as long as they hold appropriate DEA registration.

Common Side Effects of Jatenzo

In the pivotal 4-month clinical trial (n=166), the following side effects occurred in 2% or more of patients:

Headache (4.8%)

Elevated hematocrit / increased red blood cell count (4.8%)

Decreased HDL ("good") cholesterol

Hypertension / elevated blood pressure (average increase of 4.9/2.5 mm Hg; 7% of patients required new or intensified antihypertensive treatment)

Nausea

Serious Side Effects

Major adverse cardiovascular events (MACE): heart attack, stroke, cardiovascular death — greater risk in patients with pre-existing cardiovascular risk factors

Venous thromboembolism (DVT, pulmonary embolism)

Polycythemia (excess red blood cells; monitor hematocrit every 3 months)

Depression and suicidal ideation (reported in clinical trials)

Worsening of sleep apnea (especially in patients with obesity or lung disease)

Edema / fluid retention (with risk of congestive heart failure in susceptible patients)

Gynecomastia (enlarged or painful breasts)

Suppression of spermatogenesis / reduced fertility

Increased prostate cancer risk (evaluate PSA at baseline and periodically during treatment)

Final Thoughts on Jatenzo

Jatenzo represents a genuine clinical advance in testosterone replacement therapy — offering the convenience of oral dosing while avoiding the liver toxicity that made older oral testosterone products unsafe. For men with confirmed hypogonadism who prefer an oral formulation, Jatenzo is a well-validated option with 87% of patients achieving normal testosterone levels in the pivotal clinical trial.

The primary challenges with Jatenzo in 2026 are practical rather than clinical: cost, insurance access, and pharmacy stocking. Tolmar's savings programs — including the Copay Card ($0/month for commercially insured patients), coverage-denied rate ($150/month), and cash pricing ($185/month) — significantly reduce the cost barrier for most patient populations. The removal of the blood pressure boxed warning from Jatenzo's label in July 2025 may also simplify insurance prior authorization for some payers.

If you've been prescribed Jatenzo and are having difficulty finding it at a pharmacy, medfinder can call pharmacies near you and quickly identify which ones can fill your prescription. Combined with Tolmar's savings programs, most patients can make Jatenzo accessible and affordable.